Germantown: Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a non-replicating adenoviral ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

EDT Precigen (PGEN) jumps 32% to $2.44 after FDA approval of Papzimeos Published first on TheFly – the ultimate source for real-time, ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

This first approved medical therapy for RRP generates an immune response against the causative HPV strains. It uses ...

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...